You are here

Some Implantable Cardiac Devices Have Cybersecurity Flaw

Device Use Should Continue–Remote Monitoring Benefits Outweigh Cyberattack Risks

Medtronic has disclosed a potential cybersecurity risk in several of its implantable cardiac devices, including defibrillators and resynchronization therapy hardware.

The security flaw was found in the Conexus radio frequency wireless telemetry protocol, which transmits unencrypted data to program the devices or gather information from the implants.

According to Medtronic, the vulnerabilities could enable unauthorized users to access or change the settings on implantable devices, at-home monitors, or programmers in the clinic. The company stated there have been no reports of a related cyberattack, privacy breach, or harm to patients.

The affected devices include models such as the Amplia, Claria, Compia, Concerto, Consulta, and Viva CRT-D devices; Evera, Maximo II, Mirro, Nayamed ND, Primo, Protecta, Secura, Virtuoso, and Visia implantable defibrillators; and some CareLink monitors and programmers. Medtronic’s pacemakers do not use Conexus telemetry.

Medtronic, and the FDA, recommended that devices continue to be used, saying that the benefits of remote monitoring–which include earlier detection of arrhythmias, fewer hospital visits, and improved survival rates–outweigh the risks of cyberattack. To exploit the vulnerabilities, attackers would need specialized knowledge of medical devices, wireless telemetry, and electrophysiology. In addition, device activation times are limited outside the hospital/clinic, vary by patient, and would be hard to predict by an unauthorized user.

The FDA said that reprogramming or updating the devices is not required at present.

Source: FierceBiotech, March 26, 2019; Medtronic, March 21, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Drug Improved or Stabilized Symptoms, Shrank Brain Lesions